Apr 30 |
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
|
Apr 17 |
SeaStar Medical Holding GAAP EPS of -$1.21 misses by $0.60
|
Apr 17 |
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
|
Mar 27 |
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
|
Mar 12 |
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
|
Mar 11 |
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
|
Mar 6 |
Q4 2023 Nuwellis Inc Earnings Call
|
Mar 4 |
Peering Into SeaStar Medical Holding's Recent Short Interest
|
Feb 27 |
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
|
Feb 22 |
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
|